Ultime notizie per Precigen (NASDAQ:PGEN) Azioni

Precigen

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Precigen Inc

Pigeon Corp

<a href="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_04172025_NWTG_Kerr.pdf" title="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_04172025_NWTG_Kerr.pdf">https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_04172025_NWTG_Kerr.pdf</a>

News

Analyst Ratings

Trading Ideas

NWTG

Watching Newton Golf Company; Zacks Small-Cap Research Gives Stock $12 Price Valuation

UBS analyst Peter Grom maintains Helen Of Troy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) with a Neutral and lowers the price target from $68 to $38.

Price Target

HELE

UBS Maintains Neutral on Helen Of Troy, Lowers Price Target to $38

The U.K.&#8217;s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Blenrep.
Blenrep&nbsp;is approved for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide.&nbsp;
This&nbsp;U.K.&nbsp;regulatory authorization <a target="_blank" href="https://otp.tools.investis.com/generic/regulatory-story.aspx?cid=410&amp;newsid=1931677" rel="noreferrer noopener">marks</a> the first in the world for&nbsp;Blenrep&nbsp;in this treatment setting.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44496482/fda-approves-gsks-oral-antibiotic-for-urinary-tract-infections-for-females-aged-12-years-and-older" rel="noreferrer noopener">FDA Approves GSK&#8217;s Oral Antibiotic For Urinary Tract Infections For Females Aged 12 Years And Older</a>
Efficacy results from the pivotal DREAMM-7 and DREAMM-8 phase 3 trials in relapsed or refractory multiple myeloma support MHRA authorization of&nbsp;Blenrep&nbsp;combinations.
These include statistically significant and clinically meaningful progression-free survival (PFS) results for&nbsp;Blenrep&nbsp;combinations versus standards of care in both trials and overall survival (OS) in DREAMM-7.
DREAMM-7 and DREAMM-8 showed statistically significant and clinically meaningful PFS improvements for the Blenrep combinations compared to standard of care triplet combinations in the second line or later treatment of multiple myeloma.
In DREAMM-7, the&nbsp;Blenrep&nbsp;combination nearly tripled median PFS versus the daratumumab-based comparator (36.6 months versus 13.4 months, respectively.
<ul>
<li>DREAMM-7 also met the key secondary endpoint of OS, showing a statistically significant and clinically meaningful 42% reduction in the risk of death at a median follow-up of 39.4 months, favoring the Blenrep combination (n=243) versus the daratumumab-based <a href="https://www.benzinga.com/general/biotech/24/12/42420807/gsks-blood-cancer-drug-shows-improved-survival-compared-to-johnson-johnsons-darzalex" target="_blank" rel="noreferrer noopener">comparator (n=251)</a>.</li>
<li>The three-year OS rate was 74% in the Blenrep combination arm and 60% in the daratumumab combination arm. </li>
</ul>
In DREAMM-8, at a median follow-up of 21.8 months, the median PFS was not yet reached with the&nbsp;Blenrep&nbsp;combination compared to 12.7 months in the bortezomib combination.
Blenrep&nbsp;combinations are currently under review in 14 countries, including the&nbsp;U.S., with a Prescription Drug User Fee Act (PDUFA) date of 23 July 2025.
In 2022,&nbsp;GSK withdrew&nbsp;the U.S. marketing authorization for Blenrep following the FDA request, based on the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial,&nbsp;which did not meet the requirements of the FDA&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41986367/gsk-raises-prospects-for-withdrawn-blood-cancer-drug-blenrep-to-return-to-us-market-heres-why" rel="noreferrer noopener">Accelerated Approval regulations</a>.&nbsp;
Price Action: GSK stock is up 1.74% at $35.99 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44867490/evan-scott-takes-over-as-lockheed-martin-cfo-succeeding-jesus-jay-malave" target="_blank" rel="noreferrer noopener">Lockheed Martin Confirms New CFO, Evan Scott Takes Over For Jesus &#8216;Jay&#8217; Malave</a></li>
</ul>
Photo by HJBC via Shutterstock

Biotech

Large Cap

Health Care

General

UK Becomes First Country To Authorize Blenrep In Two Combo Regimens

UBS analyst Josh Silverstein maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Buy and lowers the price target from $175 to $163.

FANG

UBS Maintains Buy on Diamondback Energy, Lowers Price Target to $163

UBS analyst Josh Silverstein maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Buy and lowers the price target from $131 to $129.

UBS Maintains Buy on Expand Energy, Lowers Price Target to $129

UBS analyst Josh Silverstein maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Neutral and lowers the price target from $55 to $54.

UBS Maintains Neutral on EQT, Lowers Price Target to $54

<a href="https://explore.lnw.com/newsroom/light-wonder-invests-in-bang-bang-games/">https://explore.lnw.com/newsroom/light-wonder-invests-in-bang-bang-games/</a>

Light & Wonder Reveals An Investment Of 20% Equity In Slot Studio Bang Bang Games Limited; No Financial Terms Disclosed

UBS analyst Peter Grom maintains Energizer Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENR#NYSE">ENR</a>) with a Neutral and lowers the price target from $36 to $28.

UBS Maintains Neutral on Energizer Hldgs, Lowers Price Target to $28

UBS analyst Peter Grom maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Neutral and lowers the price target from $74 to $59.

UBS Maintains Neutral on e.l.f. Beauty, Lowers Price Target to $59

Wall Street saw a rebound in risk appetite on Thursday ahead of the long Easter weekend, as President Donald Trump signaled positive <a href="https://www.benzinga.com/topic/donald-trump">momentum in trade negotiations.</a>
Speaking ahead of a scheduled meeting with Italian Prime Minister Giorgia Meloni, Trump expressed strong confidence in reaching a trade agreement with the European Union. He also hinted at progress with China, stating, "We will make a good deal with China." 
Meanwhile, U.S. Treasury Secretary Scott Bessent noted that trade talks with Japan are moving in a highly satisfactory direction.
By midday in New York, the S&amp;P 500 had climbed 0.9%, while the Nasdaq 100 gained 0.5%, recouping some losses after a 3% slide on Wednesday. The Dow Jones, however, slipped 0.9%, weighed down by a sharp 23% plunge in UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) after the company slashed its full-year earnings forecast.
Energy stocks led the day&#8217;s gains, buoyed by rising oil prices. Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) rallied 4.1%, while Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) advanced 3.5%.
Gold prices retreated nearly 1% after a strong multi-day rally, pressured by a firmer U.S. dollar and rising Treasury yields. The 10-year Treasury yield climbed six basis points to 4.34%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged up 0.9% to $85,000.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg (%)</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,884.35</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,323.43</td>
<td>0.9%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,357.77</td>
<td>0.5%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,441.72</td>
<td colspan="2">-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.8% to $530.09.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 0.7% to $394.05.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.5% to $446.19.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 1% to $186.67.</li>
<li>The&nbsp;Energt&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 3.5%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.1%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul>
<li>Eli Lilly Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) surged 16% after announcing that its oral GLP-1 receptor agonist, Orforglipron, successfully completed Phase 3 trials without requiring food or water restrictions.</li>
<li>Fidelity National Information Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) jumped 9% after announcing a $13.5 billion deal to acquire Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)&#8217;s Issuer Solutions business. The move is aimed at bolstering FIS's fintech capabilities and is expected to generate over $125 million in annual revenue synergies. Shares of GPN tumbled 15%. </li>
<li>Companies reacting to earnings reports included American Express Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), up 0.5%; Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), up 1.9%; Charles Schwab Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), up 2.7%; Marsh &amp; McLennan Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) down 3.3%; Truist Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>), up 1.3%; State Street Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>), up 3.2%; KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>), up 3.7% and Huntington Bancshares Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>), up 4%.</li>
<li>Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) rose 2% ahead of the earnings report, which is slated for release after the market close. </li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;</a></li>
</ul>
Photo: Shutterstock

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Economics

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

HBAN

NFLX

SCHW

Wall Street Rebounds, Eli Lilly Rallies, UnitedHealth Group Plummets: What's Driving Markets Thursday?

UBS analyst Peter Grom maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Neutral and lowers the price target from $75 to $60.

UBS Maintains Neutral on Estee Lauder Cos, Lowers Price Target to $60

UBS analyst Douglas Harter maintains Ellington Credit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) with a Neutral and lowers the price target from $6.5 to $5.25.

EARN

UBS Maintains Neutral on Ellington Credit, Lowers Price Target to $5.25

Deep-pocketed investors have adopted a bullish approach towards Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FTNT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Fortinet. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $516,094, and 4 are calls, amounting to $203,157.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $77.5 to $105.0 for Fortinet over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Fortinet's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Fortinet's significant trades, within a strike price range of $77.5 to $105.0, over the past month.
<h3>Fortinet Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744912906_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FTNT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$6.8</td>
<td>$6.6</td>
<td>$6.72</td>
<td>$95.00</td>
<td>$317.0K</td>
<td align="right">957</td>
<td align="right">588</td>
</tr>
<tr>
<td>FTNT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$15.0</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$100.00</td>
<td>$81.2K</td>
<td align="right">272</td>
<td align="right">57</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$20.65</td>
<td>$20.45</td>
<td>$20.45</td>
<td>$105.00</td>
<td>$69.5K</td>
<td align="right">278</td>
<td align="right">40</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$22.7</td>
<td>$21.65</td>
<td>$21.66</td>
<td>$77.50</td>
<td>$54.1K</td>
<td align="right">32</td>
<td align="right">25</td>
</tr>
<tr>
<td>FTNT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.8</td>
<td>$6.6</td>
<td>$6.64</td>
<td>$95.00</td>
<td>$51.1K</td>
<td align="right">957</td>
<td align="right">665</td>
</tr>
</tbody>
</table>

<h3>About Fortinet</h3>
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.
Having examined the options trading patterns of Fortinet, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Fortinet</h3>
<ul>
<li>With a trading volume of 1,307,790, the price of FTNT is up by 0.37%, reaching $96.43.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 20 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Fortinet</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $106.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Stephens &amp; Co. lowers its rating to Equal-Weight with a new price target of $108. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on Fortinet with a target price of $105. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Fortinet, which currently sits at a price target of $105. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Fortinet, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

FTNT

A Closer Look at Fortinet's Options Market Dynamics

Financial giants have made a conspicuous bullish move on Nu Holdings. Our analysis of options history for Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) revealed 8 unusual trades.
Delving into the details, we found 62% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $177,620, and 6 were calls, valued at $205,382.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.0 to $15.0 for Nu Holdings over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Nu Holdings's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Nu Holdings's whale trades within a strike price range from $7.0 to $15.0 in the last 30 days. 
<h3>Nu Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744912901_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$5.15</td>
<td>$4.9</td>
<td>$4.95</td>
<td>$15.00</td>
<td>$151.9K</td>
<td>406</td>
<td>351</td>
</tr>
<tr>
<td>NU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.9</td>
<td>$3.85</td>
<td>$3.9</td>
<td>$7.00</td>
<td>$39.0K</td>
<td>214</td>
<td>100</td>
</tr>
<tr>
<td>NU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$1.82</td>
<td>$1.56</td>
<td>$1.65</td>
<td>$11.00</td>
<td>$37.9K</td>
<td>975</td>
<td>230</td>
</tr>
<tr>
<td>NU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.15</td>
<td>$0.13</td>
<td>$0.13</td>
<td>$13.00</td>
<td>$37.7K</td>
<td>24.7K</td>
<td>3.2K</td>
</tr>
<tr>
<td>NU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$1.59</td>
<td>$1.59</td>
<td>$1.59</td>
<td>$11.00</td>
<td>$35.9K</td>
<td>975</td>
<td>234</td>
</tr>
</tbody>
</table>

<h3>About Nu Holdings</h3>
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Accounts, and Rewards. The company earns the majority of its revenue in Brazil.
Following our analysis of the options activities associated with Nu Holdings, we pivot to a closer look at the company's own performance.
<h3>Nu Holdings's Current Market Status</h3>
<ul>
<li>Trading volume stands at 21,083,230, with NU's price up by 1.39%, positioned at $10.95.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 26 days.</li>
</ul>
<h3>Professional Analyst Ratings for Nu Holdings</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $13.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from JP Morgan upgrades its rating to Overweight with a revised price target of $13. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Nu Holdings options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in Nu Holdings

Investors with a lot of money to spend have taken a bearish stance on Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with APLD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Applied Digital.
This isn't normal.
The overall sentiment of these big-money traders is split between 22% bullish and 55%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $763,671, and 2 are calls, for a total amount of $56,400.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $1.0 to $7.0 for Applied Digital during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Applied Digital's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Applied Digital's substantial trades, within a strike price spectrum from $1.0 to $7.0 over the preceding 30 days.
<h3>Applied Digital Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744912896_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>APLD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.15</td>
<td>$3.1</td>
<td>$3.15</td>
<td>$7.00</td>
<td>$192.1K</td>
<td>10.5K</td>
<td>611</td>
</tr>
<tr>
<td>APLD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.15</td>
<td>$3.1</td>
<td>$3.15</td>
<td>$7.00</td>
<td>$188.3K</td>
<td>10.5K</td>
<td>1.2K</td>
</tr>
<tr>
<td>APLD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.15</td>
<td>$3.1</td>
<td>$3.15</td>
<td>$7.00</td>
<td>$146.1K</td>
<td>10.5K</td>
<td>1.6K</td>
</tr>
<tr>
<td>APLD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.2</td>
<td>$7.00</td>
<td>$123.5K</td>
<td>10.5K</td>
<td>2.0K</td>
</tr>
<tr>
<td>APLD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$2.97</td>
<td>$2.54</td>
<td>$2.84</td>
<td>$5.00</td>
<td>$60.6K</td>
<td>18.4K</td>
<td>7.5K</td>
</tr>
</tbody>
</table>

<h3>About Applied Digital</h3>
Applied Digital Corp is a designer, developer, and operator of next-generation digital infrastructure across North America. It provides digital infrastructure solutions and cloud services to industries like High-Performance Computing (HPC) and Artificial Intelligence (AI). The company operates in the following business segments; Data Center Hosting Business, Cloud Services Business, and HPC Hosting Business. The majority of its revenue is generated from the Data Center Hosting Business which operates data centers to provide energized space to crypto mining customers.
After a thorough review of the options trading surrounding Applied Digital, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Applied Digital</h3>
<ul>
<li>Trading volume stands at 22,422,785, with APLD's price down by -3.19%, positioned at $3.95.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 132 days.</li>
</ul>
<h3>Professional Analyst Ratings for Applied Digital</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $8.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Applied Digital, which currently sits at a price target of $10. 
&#x2A; Maintaining their stance, an analyst from Cantor Fitzgerald continues to hold a Overweight rating for Applied Digital, targeting a price of $7. 
&#x2A; An analyst from HC Wainwright &amp; Co. persists with their Buy rating on Applied Digital, maintaining a target price of $7. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Applied Digital with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

APLD

Behind the Scenes of Applied Digital's Latest Options Trends

UBS analyst Karl Keirstead maintains Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Neutral and lowers the price target from $90 to $85.

DOCU

UBS Maintains Neutral on Docusign, Lowers Price Target to $85

In the current market session, Loews Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>) share price is at $86.16, after a 1.13% increase. Moreover, over the past month, the stock fell by 2.60%, but in the past year, increased by 13.55%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744912875_0.png" alt="Past Year Chart" />

<h3>Evaluating Loews P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Loews has a lower P/E than the aggregate P/E of 17.47 of the Insurance industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744912875_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Loews

5 analysts have expressed a variety of opinions on Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $142.0, a high estimate of $159.00, and a low estimate of $115.00. A decline of 3.92% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1744912862_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Agilent Technologies's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $135.00&#x7C;$155.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $115.00&#x7C;$138.00 &#x7C; 
&#x7C;Catherine Schulte &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $159.00&#x7C;$161.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $145.00&#x7C;$135.00 &#x7C; 
&#x7C;Derik De Bruin &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $156.00&#x7C;$150.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Agilent Technologies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Agilent Technologies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Agilent Technologies's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/A/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Agilent Technologies analyst ratings.</a>
<h2>Delving into Agilent Technologies's Background</h2>
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
<h3>Agilent Technologies: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, Agilent Technologies showcased positive performance, achieving a revenue growth rate of 1.39% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Agilent Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.92% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Agilent Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of 5.33%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.68%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.56, Agilent Technologies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Agilent Technologies: 5 Analysts Share Their Views

Analysts' ratings for Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Blink Charging, presenting an average target of $2.71, a high estimate of $8.00, and a low estimate of $0.80. This current average has decreased by 28.5% from the previous average price target of $3.79. 
<img src="https://www.benzinga.com/files/images/story/2025/1744912855_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Blink Charging by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;William Grippin &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $0.80&#x7C;$1.00 &#x7C; 
&#x7C;Stephen Gengaro &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $2.00&#x7C;$3.50 &#x7C; 
&#x7C;Craig Irwin &#x7C;Roth MKM &#x7C;Lowers &#x7C;Buy &#x7C; $3.00&#x7C;$4.00 &#x7C; 
&#x7C;Mickey Legg &#x7C;Benchmark &#x7C;Lowers &#x7C;Buy &#x7C; $2.00&#x7C;$5.00 &#x7C; 
&#x7C;Sameer Joshi &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $8.00&#x7C;$8.00 &#x7C; 
&#x7C;Christine Cho &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $1.50&#x7C;$3.00 &#x7C; 
&#x7C;William Grippin &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $1.70&#x7C;$2.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Blink Charging. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Blink Charging compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Blink Charging's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BLNK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blink Charging analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Blink Charging</h2>
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
<h3>Blink Charging's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Blink Charging's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -29.24%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Blink Charging's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -244.28%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Blink Charging's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -46.94%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Blink Charging's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -28.22%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLNK

Deep Dive Into Blink Charging Stock: Analyst Perspectives (7 Ratings)

Analysts' ratings for JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for JPMorgan Chase, revealing an average target of $273.8, a high estimate of $305.00, and a low estimate of $251.00. Marking an increase of 0.15%, the current average surpasses the previous average price target of $273.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1744912846_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of JPMorgan Chase by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Erika Najarian &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $305.00&#x7C;$277.00 &#x7C; 
&#x7C;John McDonald &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $251.00&#x7C;$264.00 &#x7C; 
&#x7C;John McDonald &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $264.00&#x7C;$268.00 &#x7C; 
&#x7C;Ebrahim Poonawala &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $284.00&#x7C;$285.00 &#x7C; 
&#x7C;Glenn Schorr &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;Outperform &#x7C; $265.00&#x7C;$273.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to JPMorgan Chase. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of JPMorgan Chase compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of JPMorgan Chase's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of JPMorgan Chase's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JPM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on JPMorgan Chase analyst ratings.</a>
<h2>Unveiling the Story Behind JPMorgan Chase</h2>
JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with nearly $4 trillion in assets. It is organized into four major segments: consumer and community banking, corporate and investment banking, commercial banking, and asset and wealth management. JPMorgan operates, and is subject to regulation, in multiple countries.
<h3>JPMorgan Chase: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: JPMorgan Chase's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 5.89%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: JPMorgan Chase's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 31.6%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): JPMorgan Chase's ROE stands out, surpassing industry averages. With an impressive ROE of 4.36%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): JPMorgan Chase's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.34%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.88, JPMorgan Chase faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 5 Analysts Discuss JPMorgan Chase Stock

Press Releases

Precigen to Participate in the Stifel 2024 Healthcare Conference

Earnings

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Offerings

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Comments

Precigen

Notizie

Ultime notizie per Precigen (NASDAQ:PGEN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO